Safety and efficacy of sofosbuvir-based treatment of acute hepatitis C in end-stage renal disease patients undergoing haemodialysis.

about

Safety and efficacy of sofosbuvir-based treatment of acute hepatitis C in end-stage renal disease patients undergoing haemodialysis.

Item

http://www.wikidata.org/entity/Q47564403

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Safety and efficacy of sofosbu ...... ents undergoing haemodialysis.

@en

Safety and efficacy of sofosbu ...... ents undergoing haemodialysis.

@nl

type

Item

label

Safety and efficacy of sofosbu ...... ents undergoing haemodialysis.

@en

Safety and efficacy of sofosbu ...... ents undergoing haemodialysis.

@nl

prefLabel

Safety and efficacy of sofosbu ...... ents undergoing haemodialysis.

@en

Safety and efficacy of sofosbu ...... ents undergoing haemodialysis.

@nl

P1476

Safety and efficacy of sofosbu ...... ents undergoing haemodialysis.

@en

P2093

D F Ren

http://www.w3.org/2001/XMLSchema#string

H Gao

http://www.w3.org/2001/XMLSchema#string

J Dong

http://www.w3.org/2001/XMLSchema#string

L Zhu

http://www.w3.org/2001/XMLSchema#string

S J Yang

http://www.w3.org/2001/XMLSchema#string

T T Yan

http://www.w3.org/2001/XMLSchema#string

T Y Chen

http://www.w3.org/2001/XMLSchema#string

Y R Zhao

http://www.w3.org/2001/XMLSchema#string

P2860

Acute hepatitis C.

Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus.

Aspects of immune dysfunction in end-stage renal disease

Treatment of chronic hepatitis C in hemodialysis patients.

Sofosbuvir and ribavirin in acute hepatitis C-infected patient with decompensated cirrhosis.

Pharmacokinetics, safety and efficacy of a full dose sofosbuvir-based regimen given daily in hemodialysis patients with chronic hepatitis C.

Real-world effectiveness and safety of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin in hepatitis C: AMBER study.

Systematic review: cost-effectiveness of direct-acting antivirals for treatment of hepatitis C genotypes 2-6.

The frequency of acute kidney injury in patients with chronic hepatitis C virus infection treated with sofosbuvir-based regimens.

Ledipasvir plus sofosbuvir fixed-dose combination for 6 weeks in patients with acute hepatitis C virus genotype 1 monoinfection (HepNet Acute HCV IV): an open-label, single-arm, phase 2 study.

P304

526-532

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/APT.14429

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

P577

2017-12-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29250808

http://www.w3.org/2001/XMLSchema#string

P921

sofosbuvir